Theralase reaches cancer breakthrough, immunizes mice against cancer
Theralase Technologies Inc. (TSXV: TLT | OTCBB: TLTFF) reported today on new evidence supporting the benefits of its cancer therapy based on the combined use of laser light and Photo Dynamic Compounds (PDCs), demonstrating yet another time its disruptive potential in oncological treatment.
In studies conducted jointly with hospital researchers, the company provided yet more confirmation that it can protect mice against colon cancer, which, if proven in humans, may provide substantial treatment benefits and survival advantages to cancer patients.
Get our daily investorintel update
The company demonstrated in mice studies that it is able to destroy “patient-specific” cancer cells, prevent their recurrence and provide long lasting protection against local and distant metastasis, which potentially offers immense clinical benefit to cancer patients and the facilities that treat their disease.
What is most important to note is that Theralase is showing consistency with its previous results reported in March 2012 and May 2014. Those results have now been further validated with a new set of animals confirming the immune-mediated “memory response”.
In everyday language this means that Theralase has developed a process to “immunize” mice against colon cancer in the laboratory. This is encouraging to patients and fuels the hope that Theralase may provide a non invasive modality for cancer treatment that is easier on patients as it would not involve the use of surgery, radiotherapy or chemotherapy, which can require significant periods of recovery and disrupt the lives of patients and their family.
But the treatment modality is still a long way from human applications. First, there is a need for optimization of dosage and chemistry in mice. Second, there is also a need to determine how the therapy applies to other types of cancer cells as there are more than 200 different types of cancer. Cancer can develop in over 60 different organs in the body. This will take time.
But Theralase has amply demonstrated the ability to manage long-term projects. Founded in 1994, Theralase designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners such as: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been very successful in healing nerve, muscle and joint conditions in clinical practice and building on its laser expertise, Theralase’s scientists and clinicians are investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to the DNA of cancer cells and when activated with near infrared lights, destroy the cancer cells.
Dr. Luc C. Duchesne is a Speaker and Author with a PhD in Biochemistry. With three decades of scientific and business experience, he has published ... <Read more about Dr. Luc Duchesne>